

**TDMs No.** 20310 - 02

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**

**Date Report Requested:** 07/22/2009

**Test Type:** 26-39 WEEKS

3'-Azido-3'-deoxythymidine (AZT)

**Time Report Requested:** 11:50:52

**Route:** GAVAGE

**CAS Number:** 30516-87-1

**First Dose M/F:** 11/18/04 / NA

**Species/Strain:** MICE/C3B6F1-+/Trp53(tm1Brd)

**Lab:** NCTR

**C Number:** C20310C

**Lock Date:** 12/01/2008

**Cage Range:** ALL

**Date Range:** ALL

**Reasons For Removal:** ALL

**Removal Date Range:** ALL

**Treatment Groups:** Include 612 Vehicle 6 mo M                      Include 615 AZT 120 6 mo M

**Study Gender:** Male

**TDMSE Version:** 2.1.0

Test Type: 26-39 WEEKS

Time Report Requested: 11:50:52

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

<b>C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE</b>	<b>Vehicle 6 mo M</b>	<b>AZT 120 6 mo M</b>
--	-----------------------	-----------------------

**Disposition Summary**

<b>Animals Initially in Study</b>	27	26
<b>Early Deaths</b>		
<b>Moribund Sacrifice</b>		3
<b>Survivors</b>		
<b>Moribund Sacrifice</b>		1
<b>Natural Death</b>		1
<b>Terminal Sacrifice</b>	27	21
<b>Animals Examined Microscopically</b>	27	26

**ALIMENTARY SYSTEM**

Gallbladder	(26)	(26)
Intestine Large, Cecum	(27)	(26)
Hyperplasia, Lymphoid	3 [1.3]	1 [2.0]
Intestine Small, Jejunum	(27)	(26)
Liver	(27)	(26)
Fatty Change		1
Vacuolization Cytoplasmic	8 [1.1]	4 [1.0]
Pancreas	(27)	(26)
Salivary Glands	(27)	(26)
Infiltration Cellular, Lymphocyte	5 [1.0]	
Stomach, Glandular	(27)	(26)

**CARDIOVASCULAR SYSTEM**

Blood Vessel	(26)	(25)
Heart	(27)	(26)
Cardiomyopathy	2 [1.0]	

**ENDOCRINE SYSTEM**

Adrenal Cortex	(27)	(26)
Subcapsular, Hyperplasia	2 [1.0]	2 [1.0]
Thyroid Gland	(26)	(26)
Cyst		1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:50:52

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M
Infiltration Cellular, Lymphocyte		1 [1.0]
<b>GENERAL BODY SYSTEM</b>		
None		
<b>GENITAL SYSTEM</b>		
Epididymis	(27)	(26)
Preputial Gland	(27)	(26)
Atrophy		1 [3.0]
Prostate	(27)	(26)
Inflammation, Suppurative		1 [3.0]
Seminal Vesicle	(27)	(26)
Lumen, Dilatation		1 [1.0]
Testes	(27)	(26)
Seminiferous Tubule, Degeneration		1 [1.0]
<b>HEMATOPOIETIC SYSTEM</b>		
Bone Marrow	(27)	(26)
Myeloid Cell, Hyperplasia		1 [3.0]
Lymph Node	(0)	(1)
Lymph Node, Mandibular	(26)	(26)
Hyperplasia, Lymphoid	1 [1.0]	1 [1.0]
Lymph Node, Mesenteric	(27)	(25)
Hyperplasia, Lymphoid	19 [1.9]	16 [1.4]
Hyperplasia, Plasma Cell	1 [3.0]	
Spleen	(27)	(26)
Hematopoietic Cell Proliferation	1 [2.0]	2 [2.5]
Hyperplasia, Lymphoid	2 [2.0]	
Thymus	(26)	(26)
Atrophy		1 [4.0]
Hyperplasia, Lymphoid		2 [2.0]
<b>INTEGUMENTARY SYSTEM</b>		
None		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

Time Report Requested: 11:50:52

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE	Vehicle 6 mo M	AZT 120 6 mo M
<b>MUSCULOSKELETAL SYSTEM</b>		
Bone, Femur	(27)	(26)
<b>NERVOUS SYSTEM</b>		
Brain, Brain Stem	(27)	(26)
Brain, Cerebellum	(27)	(26)
Brain, Cerebrum	(27)	(26)
<b>RESPIRATORY SYSTEM</b>		
Lung	(27)	(26)
Abscess		1 [4.0]
Nose	(27)	(26)
Inflammation, Suppurative	1 [1.0]	1 [2.0]
<b>SPECIAL SENSES SYSTEM</b>		
Eye	(27)	(26)
Harderian Gland	(27)	(26)
Epithelium, Hyperplasia		1 [2.0]
<b>URINARY SYSTEM</b>		
Kidney	(27)	(26)
Bacterium		1 [2.0]
Infiltration Cellular, Lymphocyte	7 [1.0]	2 [1.0]
Inflammation, Chronic Active		1 [2.0]
Nephropathy		1 [4.0]
Pelvis, Dilatation		2 [2.0]
Transitional Epithelium, Hyperplasia	1 [1.0]	1 [2.0]
Urinary Bladder	(27)	(26)
Lumen, Dilatation	1 [3.0]	2 [2.5]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

TDMS No. 20310 - 02

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]  
3'-Azido-3'-deoxythymidine (AZT)  
CAS Number: 30516-87-1**

Date Report Requested: 07/22/2009

Test Type: 26-39 WEEKS

Time Report Requested: 11:50:52

Route: GAVAGE

First Dose M/F: 11/18/04 / NA

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lab: NCTR

---

C3B6F1-+/Trp53(tm1Brd) NCTR MICE MALE

Vehicle 6 mo M

AZT 120 6 mo M

---

\*\*\* END OF MALE \*\*\*

\*\*\* END OF REPORT \*\*\*